Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.

Journal Article (Journal Article;Review)

A prophylactic vaccine would be a powerful tool in the fight against HIV. Passive immunization of animals with broadly neutralizing antibodies (bnAbs) affords protection against viral challenge, and recent data from the Antibody Mediated Prevention clinical trials support the concept of bnAbs providing protection against HIV in humans, albeit only at broad and potent neutralizing antibody titers. Moreover, it is now clear that a successful vaccine will also need to induce bnAbs against multiple neutralizing epitopes on the HIV envelope (Env) glycoprotein. Here, we review recent clinical trials evaluating bnAb-based vaccines, and discuss key issues in the development of an HIV vaccine capable of targeting multiple Env neutralizing epitopes.

Full Text

Duke Authors

Cited Authors

  • Mu, Z; Haynes, BF; Cain, DW

Published Date

  • December 2021

Published In

Volume / Issue

  • 51 /

Start / End Page

  • 172 - 178

PubMed ID

  • 34742037

Pubmed Central ID

  • PMC9227958

Electronic International Standard Serial Number (EISSN)

  • 1879-6265

Digital Object Identifier (DOI)

  • 10.1016/j.coviro.2021.09.015


  • eng

Conference Location

  • Netherlands